ALK and non-small cell lung carcinoma: The pooled risk of developing high-grade ILD events was 3.27 (95%CI: 1.18–9.08, p = 0.023) in NSCLC patients received ALK-TKIs in comparison with chemotherapy alone (Figure 3A).